Nutra Pharma Corp (NPHC) Common Equity (2010 - 2026)

Nutra Pharma has disclosed Common Equity across 17 years of filings, most recently posting -$21.2 million for Q2 2026.

• In Q2 2026, Common Equity fell 33.95% year-over-year to -$21.2 million; the TTM figure through Jun 2026 stood at -$21.2 million (down 33.95% YoY), while the FY2025 annual figure was -$16.8 million, down 13.62% from the prior year.
• Common Equity came in at -$21.2 million for Q2 2026 at Nutra Pharma, down from -$17.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$12.4 million in Q4 2022 to a low of -$21.2 million in Q2 2026.
• Average Common Equity over 5 years is -$15.3 million, with a median of -$15.2 million recorded in 2022.
• Year-over-year, Common Equity jumped 63.23% in 2022 and slumped 33.95% in 2026.
• Over 5 years, Common Equity stood at -$12.4 million in 2022, then retreated by 11.24% to -$13.8 million in 2023, then dropped by 7.55% to -$14.8 million in 2024, then slipped by 13.62% to -$16.8 million in 2025, then dropped by 26.05% to -$21.2 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were -$21.2 million in Q2 2026, -$17.3 million in Q1 2026, and -$16.8 million in Q4 2025.